Skip to main content

Investor RelationsWealth Management:  CA  |  UK  |  AU

Menu
Travere Therapeutics Inc.
US$175m

Canaccord Genuity Acted as a Lead Manager in a Follow-On Offering for Travere Therapeutics, Inc.

​​​​​​​​​​​Transaction Overview:
Travere Therapeutics, Inc. (the “Company”) (Nasdaq:TVTX), priced its $175.2 million public offering on February 11, 2021 at a price of $26.75 per share. The Company issued 6,550,000 shares of common stock. The Underwriters exercised their option to purchase an additional 982,500 shares of common stock at the public offering price, bringing the total gross proceeds to $201.5 million, less the underwriting discounts and commissions.

 

Company Overview:
Travere is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, the Company knows the need for treatment options is urgent – that is why the global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.
Press Releases
Lead Transaction Banker

More like this

 InfraVia Capital Partners
October 2021

InfraVia Capital Partners

Exclusive Financial Adviser
View transaction detail
PharmaCann
October 2021

PharmaCann

Financial Advisor (Buy-side)
View transaction detail
Vicarious Surgical Inc.
US$872m
September 2021

Vicarious Surgical Inc.

Financial/Capital Markets Advisor
View transaction detail